Leonteq Securities AG Grows Position in Humana Inc. $HUM

Leonteq Securities AG grew its holdings in Humana Inc. (NYSE:HUM) by 185.8% in the first quarter, Holdings Channel.com reports. The institutional investor owned 8,196 shares of the insurance provider’s stock after buying an additional 5,328 shares during the quarter. Leonteq Securities AG’s holdings in Humana were worth $1,421,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of HUM. Montag A & Associates Inc. grew its stake in Humana by 1,880.0% during the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock valued at $25,000 after acquiring an additional 94 shares in the last quarter. CoreCap Advisors LLC raised its holdings in Humana by 54.4% in the 4th quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock valued at $27,000 after acquiring an additional 37 shares during the last quarter. Fideuram Asset Management Ireland dac purchased a new position in Humana in the 4th quarter worth approximately $27,000. Reflection Asset Management purchased a new position in Humana in the 4th quarter worth approximately $29,000. Finally, Rosenberg Matthew Hamilton boosted its holdings in shares of Humana by 136.0% during the 4th quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock worth $30,000 after purchasing an additional 68 shares during the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Stock Down 0.1%

HUM stock opened at $396.38 on Friday. The firm has a market cap of $47.59 billion, a PE ratio of 42.39, a PEG ratio of 2.26 and a beta of 0.71. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.77 and a current ratio of 1.77. The firm’s 50 day moving average price is $321.87 and its 200-day moving average price is $250.56. Humana Inc. has a one year low of $163.11 and a one year high of $415.00.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share for the quarter, topping the consensus estimate of $9.97 by $0.34. The company had revenue of $39.65 billion during the quarter, compared to analyst estimates of $39.37 billion. Humana had a return on equity of 10.45% and a net margin of 0.82%.The firm’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same period in the prior year, the business posted $11.58 earnings per share. Humana has set its FY 2026 guidance at 9.000- EPS. On average, equities research analysts anticipate that Humana Inc. will post 9.03 EPS for the current year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, June 26th. Humana’s dividend payout ratio (DPR) is presently 37.86%.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on HUM. TD Cowen upped their price target on Humana from $173.00 to $211.00 and gave the company a “hold” rating in a research report on Friday, May 1st. Piper Sandler reiterated a “neutral” rating and set a $254.00 price objective (up from $182.00) on shares of Humana in a research report on Wednesday, May 13th. UBS Group reissued a “neutral” rating on shares of Humana in a research note on Monday, June 15th. Mizuho raised their target price on Humana from $335.00 to $390.00 and gave the stock an “outperform” rating in a research note on Monday, June 8th. Finally, Barclays lifted their price target on Humana from $180.00 to $344.00 and gave the stock an “equal weight” rating in a report on Tuesday, May 26th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, sixteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Humana presently has a consensus rating of “Hold” and an average target price of $293.09.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.